ReviewAsian journal of urology2019
Diagnosis of prostate cancer.
Review in Asian journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches.Prostate cancer and prostatic diseases · 2022Pooled it
- MRI/Transrectal Ultrasound Fusion-Guided Targeted Biopsy and Transrectal Ultrasound-Guided Systematic Biopsy for Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis.Frontiers in oncology · 2022Pooled it
- The Role of the Metzincin Superfamily in Prostate Cancer Progression: A Systematic-Like Review.International journal of molecular sciences · 2021Pooled it
- An Assessment of PI-RADS v2.1: Inter-Reader Agreement, Diagnostic Accuracy, and the Added Value of PSA Density in Prostate Cancer Prediction.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Diagnosis of Prostate Cancer: A Comparative Evaluation of Biological Techniques.Diseases (Basel, Switzerland) · 2026Review
- Multiparametric MRI findings, PI-RADS scores, and gleason scores in prostate cancer patients at Kumasi, Ghana: a cross-sectional analysis.BMC medical imaging · 2026Article
- Synthesis, radiolabeling, and biodistribution evaluation of novel hyperbranched polyglycerols-based radiotracers for targeting PSMA in prostate cancer.Iranian journal of basic medical sciences · 2026Article
- Transperineal 3T MRI-guided and transrectal MRI-ultrasound fusion prostate biopsies: Do lesion location and size impact diagnostic yield?Urologic oncology · 2026Article
- Noncoding RNA in Clinical Trials: Diagnostic and Therapeutical Prospects.Experientia supplementum (2012) · 2026Review
- Quality of life assessment among ethnically diverse Black prostate cancer survivors: a constructivist grounded theory approach.Journal of cancer survivorship : research and practice · 2025Article
- Single-layer biosensor for urinary prostate-cancer biomarkers through transition-metal-doped graphene: a DFT study.RSC advances · 2025Article
- Deep learning assisted identification of SCUBE2 and SLC16 A5 combination in RNA-sequencing data as a novel specific potential diagnostic biomarker in prostate cancer.Medical & biological engineering & computing · 2025Article
- Elucidating the Role of MicroRNA 1827 as Diagnostic Biomarker in Prostate Cancer Progression.Applied biochemistry and biotechnology · 2025Article
- Radiologic Assessment of Periprostatic Fat as an Indicator of Prostate Cancer Risk on Multiparametric MRI.Bioengineering (Basel, Switzerland) · 2025Article
- Urinary Extracellular Vesicle Signatures as Biomarkers in Prostate Cancer Patients.International journal of molecular sciences · 2025Article
- Time-Resolved Förster Resonance Energy Transfer Nanoassay Based on CdTe Quantum Dots for Sensitive Detection of Prostate Cancer Antigen 3.ACS applied nano materials · 2025Article
- [The effect of PSMA PET/CT performed in primary staging on the clinical decision].Magyar onkologia · 2025Article
- EpiSwitch PSE Blood Test Reduces Unnecessary Prostate Biopsies: A Real-World Clinical Utility Study.Cancers · 2025Article
- Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.Pharmaceuticals (Basel, Switzerland) · 2025Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosis of prostate cancer (PCa) and adequate staging play a fundamental role for clinical and patient care. Despite major advances in biology and imaging, rectal examination and prostate-specific antigen (PSA) blood test remain the cornerstone for screening, and multiparametricmagnetic resonance imaging (mpMRI) for local staging. Recent advances in mpMRI lead to standardised interpretation and increased prescription by clinicians in order to improve detection of clinically significant PCa and select patients requiring targeted biopsies. However its indication remains controversial in biopsy-naïve patients. Nuclear medicine is also in a continuous evolution and utilisation of new radiopharmaceutical agent like choline or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.